These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
463 related articles for article (PubMed ID: 25441408)
1. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. Hickish T; Cassidy J; Propper D; Chau I; Falk S; Ford H; Iveson T; Braun M; Potter V; Macpherson IR; Finnigan H; Lee C; Jones H; Harrison M Eur J Cancer; 2014 Dec; 50(18):3136-44. PubMed ID: 25441408 [TBL] [Abstract][Full Text] [Related]
2. FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study. Douillard JY; Zemelka T; Fountzilas G; Barone C; Schlichting M; Heighway J; Eggleton SP; Srimuninnimit V Clin Colorectal Cancer; 2014 Mar; 13(1):14-26.e1. PubMed ID: 24370353 [TBL] [Abstract][Full Text] [Related]
3. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933 [TBL] [Abstract][Full Text] [Related]
4. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Stintzing S; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Jäger E; Heintges T; Stoll C; Giessen C; Modest DP; Neumann J; Jung A; Kirchner T; Scheithauer W; Heinemann V Ann Oncol; 2012 Jul; 23(7):1693-9. PubMed ID: 22219013 [TBL] [Abstract][Full Text] [Related]
5. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142 [TBL] [Abstract][Full Text] [Related]
6. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. Brodowicz T; Ciuleanu TE; Radosavljevic D; Shacham-Shmueli E; Vrbanec D; Plate S; Mrsic-Krmpotic Z; Dank M; Purkalne G; Messinger D; Zielinski CC Ann Oncol; 2013 Jul; 24(7):1769-1777. PubMed ID: 23559149 [TBL] [Abstract][Full Text] [Related]
7. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. Tveit KM; Guren T; Glimelius B; Pfeiffer P; Sorbye H; Pyrhonen S; Sigurdsson F; Kure E; Ikdahl T; Skovlund E; Fokstuen T; Hansen F; Hofsli E; Birkemeyer E; Johnsson A; Starkhammar H; Yilmaz MK; Keldsen N; Erdal AB; Dajani O; Dahl O; Christoffersen T J Clin Oncol; 2012 May; 30(15):1755-62. PubMed ID: 22473155 [TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C; Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C Oncology; 2014; 87(1):7-20. PubMed ID: 24968756 [TBL] [Abstract][Full Text] [Related]
10. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504 [TBL] [Abstract][Full Text] [Related]
11. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Élez E; Kocáková I; Höhler T; Martens UM; Bokemeyer C; Van Cutsem E; Melichar B; Smakal M; Csőszi T; Topuzov E; Orlova R; Tjulandin S; Rivera F; Straub J; Bruns R; Quaratino S; Tabernero J Ann Oncol; 2015 Jan; 26(1):132-140. PubMed ID: 25319061 [TBL] [Abstract][Full Text] [Related]
12. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462 [TBL] [Abstract][Full Text] [Related]
13. Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: effect of KRAS mutation on treatment efficacy in Taiwanese patients. Chen MC; Chiang FF; Wang HM Neoplasma; 2013; 60(5):561-7. PubMed ID: 23790176 [TBL] [Abstract][Full Text] [Related]
14. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). Fernandez-Plana J; Pericay C; Quintero G; Alonso V; Salud A; Mendez M; Salgado M; Saigi E; Cirera L; BMC Cancer; 2014 Nov; 14():865. PubMed ID: 25417182 [TBL] [Abstract][Full Text] [Related]
15. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. Richards D; Kocs DM; Spira AI; David McCollum A; Diab S; Hecker LI; Cohn A; Zhan F; Asmar L Eur J Cancer; 2013 Sep; 49(13):2823-31. PubMed ID: 23747051 [TBL] [Abstract][Full Text] [Related]
16. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. Segelov E; Waring P; Desai J; Wilson K; Gebski V; Thavaneswaran S; Elez E; Underhill C; Pavlakis N; Chantrill L; Nott L; Jefford M; Khasraw M; Day F; Wasan H; Ciardiello F; Karapetis C; Joubert W; van Hazel G; Haydon A; Price T; Tejpar S; Tebbutt N; Shapiro J BMC Cancer; 2016 May; 16():339. PubMed ID: 27246726 [TBL] [Abstract][Full Text] [Related]
17. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028 [TBL] [Abstract][Full Text] [Related]
18. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573 [TBL] [Abstract][Full Text] [Related]
19. The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. Sommeijer DW; Karapetis CS; Zalcberg JR; Tu D; Jonker DJ; Simes J; Tebbutt N; Yip D; Price TJ; O'Callaghan CJ Acta Oncol; 2014 Jul; 53(7):877-84. PubMed ID: 24495042 [TBL] [Abstract][Full Text] [Related]
20. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]